Sanofi to pay $1 billion upfront to expand antibody partnership with Regeneron

Sanofi announced it will provide Regeneron with a $1 billion upfront payment to broaden their existing antibody collaboration.

The agreement is timed as the patent protection for Dupixent, the joint immunology blockbuster, approaches expiration, prompting Sanofi to reinforce the partnership.

Under the expanded deal the companies will pursue new antibody-based therapies in immunology, leveraging Regeneron's platform to bolster Sanofi’s pipeline.